摘要
[目的]研究非小细胞肺癌(NSCLC)组织中versican蛋白的表达,探讨其与NSCLC临床病理参数及预后之间的关系。[方法]应用免疫组化方法检测80例NSCLC组织中versican蛋白表达水平,并对其与患者的临床病理特征及总生存时间(OS)关系进行分析。[结果]80例NSCLC肿瘤组织中,versican蛋白全部表达,其中强阳性表达率36.3%(29/80),弱阳性表达率63.7%(51/80)。Versican蛋白在晚期NSCLC中的强阳性表达率显著高于早期NSCLC(P=0.006)。Versican蛋白强阳性和弱阳性表达患者的中位生存时间(MST)分别为12和22个月(P=0.000)。单因素分析的结果显示,NSCLS患者的预后与肿瘤分期、淋巴结转移、分化程度、versican蛋白表达水平密切相关(P均<0.05)。Cox比例风险回归模型进行多因素分析的结果显示,肿瘤分期、淋巴结转移状态和versican蛋白的表达水平是影响NSCLC患者预后的独立因素(P均<0.05)。[结论]Versican蛋白的表达情况是NSCLC的独立预后因素,与患者的预后呈负相关。
[Purposel To investigate the expression of versican in non-small cell lung cancer （NSCLC） tissues and its correlation with elinicopathological features and prognosis. [Methods] The expression of versican in 80 cases of tissue samples from NSCLC was detected immunohistochemically. The correlation of the expression of versican with clinicopathalogical features and overall survival （OS） of the NSCLC patients was analyzed. [Results] Versican protein was all expressed in 80 NSCLC tissue samples,with strong positive expression rate of 36.3%（29/80）,and weak positive expression rate of 63.7%（51/80）. The strong positive expression rate of versiean in advanced NSCLC was significantly higher than that in early stage NSCLC （P=0.006）.The median survival time （MST） was 12 months and 22 months respectively in patients with high positive expression of versiean and in patients with weak positive expression of versican （P=0.000）. Univari- ate analysis revealed that TNM stage,lymph nodes status, differentiation grade and versican expression were significantly associated with prognosis of NSCLC patients （P〈0.05）. The Cox multivariate analysis demonstrated that TNM stage,lymph node status and versican expression were independent prognostic factors. [Conclusion ] Versican expression is independent prognostic factor for NSCLC , and is negatively correlated with prognosis.
出处
《肿瘤学杂志》
CAS
2014年第10期787-791,共5页
Journal of Chinese Oncology
基金
南京医科大学科技发展基金面上项目(2012NJMU174)
